daclatasvir Articles

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting

24 April 2013

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon

23 April 2013

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress

9 April 2013

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head

8 April 2013

Bristol-Myers daclatasvir combo achieves 94% response in hep C patients

13 November 2012

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

18 April 2012

Bristol-Myers links with Tibotec for Ph II combination study in hepatitis C patients

5 December 2011

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end